Patents by Inventor Eun-Ji Yang
Eun-Ji Yang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10851346Abstract: The present invention relates to a mesenchymal stem cell having immunomodulatory activity and a preparation method therefor and, more specifically, to: a rapamycin-treated mesenchymal stem cell having immunomodulatory activity, which expresses any one or more cell surface factors selected from the group consisting of CCR1, CCR2, CCR3, CCR4, CCR7, CCR9 and CXCR4; a cell therapy composition comprising the mesenchymal stem cell, for preventing or treating immune disorders; and a preparation method for the mesenchymal stem cell having immunomodulatory activity. The rapamycin-treated mesenchymal stem cell having immunomodulatory activity, according to the present invention, has increased expression of IDO, TGF-? and IL-10 which are factors having immunomodulatory activity, has decreased expression of Phospho-mTOR, Rictor and Ractor which are signal transduction factors of mTOR, and has increased expression, in the cell, of autophagic inducer Beclin1, ATG5, ATG7, LC3I or LCII.Type: GrantFiled: August 14, 2014Date of Patent: December 1, 2020Assignee: THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY—ACADEMIC COOPERATION FOUNDATIONInventors: Chul Woo Yang, Mi-La Cho, Sung-Hwan Park, Eun Kyung Kim, Byung Ha Chung, Kyoung-Woon Kim, Seon-Yeong Lee, Sung-Hee Lee, Eun Ji Yang, Jeong-hee Jeong, Min Jung Park, Seok-Jung Kim, Eun-Jung Lee, Su-Jin Moon
-
Patent number: 10716771Abstract: The present invention relates to a biguanide derivative compound capable of effectively preventing and treating immune diseases. The biguanide-based derivative compound according to the present invention inhibits the generation of IL-17 and TNF-?, which are inflammatory cytokines, increases the activity of regulatory T cells having an immunomodulatory function, and exhibits excellent therapeutic effects in animal models of immune diseases. Accordingly, the biguanide-based derivative compound can be usefully used as an immunosuppressant or a pharmaceutical composition capable of preventing or treating various immune diseases, such as autoimmune diseases, inflammatory diseases, and transplant rejection, caused by the dysregulation of immune responses.Type: GrantFiled: June 19, 2019Date of Patent: July 21, 2020Assignee: THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC CORPORATION FOUNDATIONInventors: Mi-La Cho, Chul-Woo Yang, Dong-Yun Shin, Min-Jung Park, Seon-Yeong Lee, Sung-Hee Lee, Eun-Ji Yang, Hye-Jin Son, Eun-Kyung Kim, Jae-Kyung Kim
-
Publication number: 20190328685Abstract: The present invention relates to a biguanide derivative compound capable of effectively preventing and treating immune diseases. The biguanide-based derivative compound according to the present invention inhibits the generation of IL-17 and TNF-?, which are inflammatory cytokines, increases the activity of regulatory T cells having an immunomodulatory function, and exhibits excellent therapeutic effects in animal models of immune diseases. Accordingly, the biguanide-based derivative compound can be usefully used as an immunosuppressant or a pharmaceutical composition capable of preventing or treating various immune diseases, such as autoimmune diseases, inflammatory diseases, and transplant rejection, caused by the dysregulation of immune responses.Type: ApplicationFiled: June 19, 2019Publication date: October 31, 2019Applicant: THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATIONInventors: Mi-La Cho, Chul-Woo Yang, Dong-Yun Shin, Min-Jung Park, Seon-Yeong Lee, Sung-Hee Lee, Eun-Ji Yang, Hye-Jin Son, Eun-Kyung Kim, Jae-Kyung Kim
-
Patent number: 10369121Abstract: The present invention relates to a biguanide derivative compound capable of effectively preventing and treating immune diseases. The biguanide-based derivative compound according to the present invention inhibits the generation of IL-17 and TNF-?, which are inflammatory cytokines, increases the activity of regulatory T cells having an immunomodulatory function, and exhibits excellent therapeutic effects in animal models of immune diseases. Accordingly, the biguanide-based derivative compound can be usefully used as an immunosuppressant or a pharmaceutical composition capable of preventing or treating various immune diseases, such as autoimmune diseases, inflammatory diseases, and transplant rejection, caused by the dysregulation of immune responses.Type: GrantFiled: August 25, 2014Date of Patent: August 6, 2019Assignee: The Catholic University of Korea Industry-Academic Cooperation FoundationInventors: Mi-La Cho, Chul-Woo Yang, Dong-Yun Shin, Min-Jung Park, Seon-Yeong Lee, Sung-Hee Lee, Eun-Ji Yang, Hye-Jin Son, Eun-Kyung Kim, Jae-Kyung Kim
-
Publication number: 20170333370Abstract: The present invention relates to a biguanide derivative compound capable of effectively preventing and treating immune diseases. The biguanide-based derivative compound according to the present invention inhibits the generation of IL-17 and TNF-?, which are inflammatory cytokines, increases the activity of regulatory T cells having an immunomodulatory function, and exhibits excellent therapeutic effects in animal models of immune diseases. Accordingly, the biguanide-based derivative compound can be usefully used as an immunosuppressant or a pharmaceutical composition capable of preventing or treating various immune diseases, such as autoimmune diseases, inflammatory diseases, and transplant rejection, caused by the dysregulation of immune responses.Type: ApplicationFiled: August 25, 2014Publication date: November 23, 2017Applicant: THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATIONInventors: Mi-La CHO, Chul-Woo YANG, Dong-Yun SHIN, Min-Jung PARK, Seon-Yeong LEE, Sung-Hee LEE, Eun-Ji YANG, Hye-Jin SON, Eun-Kyung KIM, Jae-Kyung KIM
-
Patent number: 9700531Abstract: The present invention relates to a composition comprising metformin as an active ingredient for preventing or treating inflammatory bowel disease. The metformin compound or the metformin-etanercept (product name: Enbrel) composite according to the present invention may have excellent effects of maintaining the thickness of the small intestine and length of the large intestine normal, inhibiting or decreasing the activity of IL-17 and TNF-a, and promoting or increasing the activity of IFNr, and therefore can be effectively used as a pharmaceutical composition for preventing or treating autoimmune diseases including inflammatory bowel disease.Type: GrantFiled: March 19, 2015Date of Patent: July 11, 2017Assignee: Catholic University Industry Academic Cooperation FoundationInventors: Mi-La Cho, Seon-Yeong Lee, Eun-Ji Yang, Hye-Jin Son, Eun-Kyung Kim, Jun-Geol Ryu
-
Publication number: 20170157069Abstract: The present invention relates to a composition for preventing or treating immune diseases through the suppression of B cell activity induced by metformin. More particularly, the present invention relates to a composition comprising a metformin compound or a pharmaceutically acceptable salt thereof as an active ingredient for preventing or treating immune diseases, wherein the composition is characterized by suppression or reduction of B cell activity which is a cause of disease. The present invention can be valuable in the use thereof for various autoimmune diseases as an immunosuppressant which can prevent or treat immune diseases by suppressing or reducing B cell activity and Th17 cell activity, which are causes of disease, or by promoting or increasing regulatory T cell activity.Type: ApplicationFiled: February 23, 2017Publication date: June 8, 2017Applicant: CATHOLIC UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATIONInventors: Mi-La CHO, Seon-Yeong LEE, Min-Jung PARK, Jae-Seon LEE, Eun-Ji YANG, Eun-Kyung KIM, Jun-Geol RYU, Hye-Jin SON
-
Patent number: 9585945Abstract: The present invention relates to a composition for preventing or treating an autoimmune disease comprising, as an active ingredient, PINK1 protein or polynucleotide encoding the same. The PINK1 protein according to the present invention inhibits the activity of Th17, promotes the activity of a regulatory T cell (Treg), and increases autophagy in Treg cells, thereby controlling excessive immune responses. Therefore, the PINK1 protein can be effectively used as a pharmaceutical composition or an immunosuppressant, which is capable of preventing or treating an autoimmune disease, such as arthritis, and the like, caused by dysregulation of various kinds of immune responses.Type: GrantFiled: November 20, 2015Date of Patent: March 7, 2017Assignee: CATHOLIC UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATIONInventors: Mi-La Cho, Hyang-Suk Rhim, Seon-Yeong Lee, Yeong-Mi Mun, Hye-Jin Son, Eun-Ji Yang, Eun-Kyung Kim
-
Patent number: 9526717Abstract: The daurinol compound according to the present invention exhibits excellent therapeutic effects on arthritis and inflammatory bowel diseases by having an excellent activity in inhibiting the generation of IL-17 and TNF-?, which are inflammatory cytokines causing inflammation, and can alleviate transplant rejection by inhibiting the proliferation of alloreactive T cells and increasing regulatory T cells; therefore, the daurinol compound according to the present invention can be used as a pharmaceutical composition capable of treating and preventing immune diseases. In addition, being a natural substance derived from the Mongolian medicinal plant Haplophyllum dauricum or Haplophyllum cappadocicum, the daurinol compound according to the present invention does not cause cytotoxicity and thus may be used as a composition for a functional health food capable of preventing and remedying immune diseases.Type: GrantFiled: August 22, 2014Date of Patent: December 27, 2016Assignee: THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION, CATHOLIC UNIV. OF KOREA SONGEUI CAMPUSInventors: Mi-La Cho, Dong-Yun Shin, Min-Jung Park, Seon-Yeong Lee, Eun Ji Yang, Eun Kyung Kim, Hye-Jin Son, Eun-Jung Lee, Jae-Kyung Kim, Sung-Hee Lee
-
Publication number: 20160289640Abstract: The present invention relates to a mesenchymal stem cell having immunomodulatory activity and a preparation method therefor and, more specifically, to: a rapamycin-treated mesenchymal stem cell having immunomodulatory activity, which expresses any one or more cell surface factors selected from the group consisting of CCR1, CCR2, CCR3, CCR4, CCR7, CCR9 and CXCR4; a cell therapy composition comprising the mesenchymal stem cell, for preventing or treating immune disorders; and a preparation method for the mesenchymal stem cell having immunomodulatory activity. The rapamycin-treated mesenchymal stem cell having immunomodulatory activity, according to the present invention, has increased expression of IDO, TGF-? and IL-10 which are factors having immunomodulatory activity, has decreased expression of Phospho-mTOR, Rictor and Ractor which are signal transduction factors of mTOR, and has increased expression, in the cell, of autophagic inducer Beclin1, ATG5, ATG7, LC3I or LCII.Type: ApplicationFiled: August 14, 2014Publication date: October 6, 2016Inventors: Chul Woo YANG, Mi-La CHO, Sung-Hwan PARK, Eun Kyung KIM, Byung Ha CHUNG, Kyoung-Woon KIM, Seon-Yeong LEE, Sung-Hee LEE, Eun Ji YANG, Jeong-hee JEONG, Min Jung PARK, Seok-Jung KIM, Eun-Jung LEE, Su-Jin MOON
-
Publication number: 20160193180Abstract: The daurinol compound according to the present invention exhibits excellent therapeutic effects on arthritis and inflammatory bowel diseases by having an excellent activity in inhibiting the generation of IL-17 and TNF-?, which are inflammatory cytokines causing inflammation, and can alleviate transplant rejection by inhibiting the proliferation of alloreactive T cells and increasing regulatory T cells; therefore, the daurinol compound according to the present invention can be used as a pharmaceutical composition capable of treating and preventing immune diseases. In addition, being a natural substance derived from the Mongolian medicinal plant Haplophyllum dauricum or Haplophyllum cappadocicum, the daurinol compound according to the present invention does not cause cytotoxicity and thus may be used as a composition for a functional health food capable of preventing and remedying immune diseases.Type: ApplicationFiled: August 22, 2014Publication date: July 7, 2016Applicant: The Catholic University of Korea Industry-Academic Cooperation FoundationInventors: Mi-La CHO, Dong-Yun SHIN, Min-Jung PARK, Seon-Yeong LEE, Eun Ji YANG, Eun Kyung KIM, Hye-Jin SON, Eun-Jung LEE, Jae-Kyung KIM, Sung-Hee LEE
-
Publication number: 20160114007Abstract: The present invention relates to a composition for preventing or treating an autoimmune disease comprising, as an active ingredient, PINK1 protein or polynucleotide encoding the same. The PINK1 protein according to the present invention inhibits the activity of Th17, promotes the activity of a regulatory T cell (Treg), and increases autophagy in Treg cells, thereby controlling excessive immune responses. Therefore, the PINK1 protein can be effectively used as a pharmaceutical composition or an immunosuppressant, which is capable of preventing or treating an autoimmune disease, such as arthritis, and the like, caused by dysregulation of various kinds of immune responses.Type: ApplicationFiled: November 20, 2015Publication date: April 28, 2016Inventors: Mi-La Cho, Hyang-Suk Rhim, Seon-Yeong Lee, Yeong-Mi Mun, Hye-Jin Son, Eun-Ji Yang, Eun-Kyung Kim
-
Publication number: 20150297676Abstract: The present invention relates to a composition comprising GRIM-19 protein as an active ingredient for preventing or treating obesity or lipid-related metabolic diseases. More particularly, the present invention relates to a composition for preventing or treating obesity or lipid-related metabolic diseases wherein the composition comprises GRIM-19 protein as an active ingredient for preventing or treating metabolic diseases caused by immune response disorders or interactions between genetic, metabolic, or environmental complex factors. The GRIM-19 protein according to the present invention exhibits excellent effectiveness not only in reducing lipocytes and total cholesterol content in the body, but also in suppressing the differentiation of cytotoxic Th17 cells that produce and secrete inflammatory cytokines. Also, GRIM-19 has been found to have excellent effectiveness in regulating a STAT3 mediated inflammatory response in an inflammatory environment related to obesity.Type: ApplicationFiled: September 2, 2013Publication date: October 22, 2015Applicant: Catholic University Industry Academic Cooperation FoundationInventors: Mi-La CHO, Joo-Yeon Jhun, Seon-Yeong Lee, Yeong-Mi Mun, Jun-Geol Ryu, Jae-Kyeong Byun, Hye-Jin Son, Eun-Kyung Kim, Eun-Ji Yang, Jeong-Hee Jeong
-
Publication number: 20150238445Abstract: The present invention relates to a composition for preventing or treating immune diseases through the suppression of B cell activity induced by metformin. More particularly, the present invention relates to a composition comprising a metformin compound or a pharmaceutically acceptable salt thereof as an active ingredient for preventing or treating immune diseases, wherein the composition is characterized by suppression or reduction of B cell activity which is a cause of disease. The present invention can be valuable in the use thereof for various autoimmune diseases as an immunosuppressant which can prevent or treat immune diseases by suppressing or reducing B cell activity and Th17 cell activity, which are causes of disease, or by promoting or increasing regulatory T cell activity.Type: ApplicationFiled: September 6, 2013Publication date: August 27, 2015Inventors: Mi-La Cho, Seon-Yeong Lee, Min-Jung Park, Jae-Seon Lee, Eun-Ji Yang, Eun-Kyung Kim, Jun-Geol Ryu, Hye-Jin Son
-
Publication number: 20150196511Abstract: The present invention relates to a composition comprising metformin as an active ingredient for preventing or treating inflammatory bowel disease. The metformin compound or the metformin-etanercept (product name: Enbrel) composite according to the present invention may have excellent effects of maintaining the thickness of the small intestine and length of the large intestine normal, inhibiting or decreasing the activity of IL-17 and TNF-a, and promoting or increasing the activity of IFNr, and therefore can be effectively used as a pharmaceutical composition for preventing or treating autoimmune diseases including inflammatory bowel disease.Type: ApplicationFiled: March 19, 2015Publication date: July 16, 2015Inventors: Mi-La Cho, Seon-Yeong Lee, Eun-Ji Yang, Hye-Jin Son, Eun-Kyung Kim, Jun-Geol Ryu